Article

MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA

Ya-Ling Yang 1, Ming-Chao Tsai 2, Yen-Hsiang Chang 3,4, Chen-Chen Wang 5, Pei-Yi Chu 6,7,8,9,*,**, Hung-Yu Lin 5,* and Ying-Hsien Huang 10,*

Abstract: Primary liver cancer accounts for the third most deadly type of malignant tumor globally, and approximately 80% of the cases are hepatocellular carcinoma (HCC), which highly relies on the activity of hypoxia responsive pathways to bolster its metastatic behaviors. MicroRNA-29a (MIR29A) has been shown to exert a hepatoprotective effect on hepatocellular damage and liver fibrosis induced by cholestasis and diet stress, while its clinical and biological role on the activity hypoxia responsive genes including LOX, LOXL2, and VEGFA remains unclear. TCGA datasets were retrieved to confirm the differential expression and prognostic significance of all genes in the HCC and normal tissue. The Gene Expression Omnibus (GEO) dataset was used to corroborate the differential expression and diagnostic value of MIR29A. The bioinformatic identification were conducted to examine the interaction of MIR29A with LOX, LOXL2, and VEGFA. The suppressive activity of MIR29A on LOX, LOXL2, and VEGF was verified by qPCR, immunoblotting, and luciferase. The effect of overexpression of MIR29A-3p mimics in vitro on apoptosis markers (caspase-9, -3, and poly (ADP-ribose) polymerase (PARP)); cell viability and wound healing performance were examined using immunoblot and a WST-1 assay and a wound healing assay, respectively. The HCC tissue presented low expression of MIR29A, yet high expression of LOX, LOXL2, and VEGFA as compared to normal control. Serum MIR29A of HCC patients showed decreased levels as compared to that of normal control, with an area under curve (AUC) of 0.751 of a receiver operating characteristic (ROC) curve. Low expression of MIR29A and high expression of LOX, LOXL2, and VEGF indicated poor overall survival (OS). MIR29A-3p was shown to target the 3′UTR of LOX, LOXL2, and VEGFA. Overexpression of MIR29A-3p mimic in HepG2 cells led to downregulated gene and protein expression levels of LOX, LOXL2, and VEGFA, wherein luciferase reporter assay confirmed that MIR29A-3p exerts the inhibitory activity via directly binding to the 3′UTR of LOX and VEGFA. Furthermore, overexpression of MIR29A-3p mimic induced the activity of caspase-9 and -3 and PARP, while it inhibited the cell viability and wound healing performance. Collectively, this study provides novel insight into a clinical-applicable panel consisting of MIR29, LOX, LOXL2, and VEGFA and demonstrates an anti-HCC effect of MIR29A via comprehensively suppressing the expression of LOX, LOXL2, and VEGFA, paving the way to a prospective theragnostic approach for HCC.
Keywords: microRNA-29a; hepatocellular carcinoma; metastasis; lysyl oxidase; lysyl oxidase like 2; vascular endothelial growth factor A; diagnosis; prognosis

1. Introduction

Primary liver cancer accounts for the third most deadly type of malignant tumor globally and approximately 80% of the cases are hepatocellular carcinoma (HCC) [1,2]. To date, despite the availability of many different therapeutic interventions, such as surgical resection, liver transplantation, radiofrequency ablation, chemoembolization, and target therapy [3], the prognosis of HCC remains poor, with a five-year overall survival (OS) rate below 20% [1]. One of the key factors is its propensity for metastatic progression and poor response to pharmacological approaches [3]. As such, the identification of promising theragnostic targets to improve the prognosis of the HCC patients is of vital importance.

The lysyl oxidase family members are secreted copper-dependent oxidases, including five paralogues: LOX, LOX-like 1–4 (LOXL1–4), which act to exert catalytic activity to remodel the cross-linking of the extracellular matrix (ECM) of fibrotic liver and that of a corrupted tumor microenvironment (TME) [4]. To date, the roles of LOX and LOXL2 in the clinical significance and therapeutic implication of HCC are mostly studied as compared to the other family members [5]. The fact that LOX and LOXL2 serving as critical factors in mediating the formation of a corrupted TME and promoting the progression of metastasis of HCC through activating pathways involved in hypoxia responsive signaling and angiogenesis, and epithelial mesenchymal transition (EMT) has been highlighted [5]. For example, LOX acts to mediate angiogenesis via increasing the secreted vascular endothelial growth factor A (VEGFA) from HCC cells [6] and to augment metastatic behaviors by activating EMT program [7]. On the other hand, LOXL2 was reported to activate the process of angiogenesis through upregulating the HIF-1α/VEGF pathway [8] and promote HCC metastasis to distant organ via an AKT/fibronectin-dependent pathway [9]. Given the biological importance of LOX, LOXL2, and VEGFA in the cancer progression, a variety of targeting drugs has currently been evaluated in clinical trials [5,10–12]. Nonetheless, a treatment approach that can comprehensively targeting these factors to render therapeutic potential for the treatment of HCC is yet to be identified.

MicroRNAs (miRNAs), a large family of small non-coding RNAs, was reported to feature diverse and crucial effect on the development and metastasis of HCC by targeting the 3′ untranslated region (3′UTR) of a variety of genes [13]. MIR29 family members consist of MIR29A, MIR29B, and MIR29C. The UCU sequence of MIR29A results in its high stability as compared to the rapid decay of MIR29B and MIR29C caused by the presence of UUU tri-uracil sequence [14]. The MIR29A expression features clinical significance in a variety of disease scenarios, including Alzheimer’s disease [15], Parkinson’s disease [16], ankylosing spondylitis [17], atherosclerosis [18], atrial fibrillation [19], active pulmonary tuberculosis [20], thoracic aneurysms [21], tendon disease [22], diabetes [23], scleroderma [24], cholestatic pediatric liver disease [25], and non-alcoholic fatty liver disease (NAFLD) [26]. Importantly, our previous studies have reported the hepatoprotective role of MIR29A in the scenario of cholestasis- or diet-induced steatohepatitis and liver fibrosis [27–38], and growing evidence has revealed its regulatory role on HCC metastasis [13,39]. In terms of biological activity, MIR29A was reported to directly target VEGFA to perturb the wound healing process [40], and to directly target LOXL2 to impede tumor progression [41]. In this study, we demonstrated that MIR29A, along with LOX, LOXL2, and VEGFA, exhibits diagnostic and prognostic significance and that overexpression of MIR29A notably contributes to suppression of cellular metastatic behaviors by comprehensively targeting the 3′UTR of the aforementioned genes, offering novel insights into the MIR29A-involved signaling in the development of a practical diagnostic/prognostic panel and a therapeutic strategy.
2. Results

2.1. The Aberrant Expression and the Prognostic Value of MIR29A, LOX, LOXL2, and VEGFA in HCC Patients

We firstly examined the MIR29A expression levels in HCC and normal tissue by accessing the TCGA datasets in the OncoMir Cancer Database (OMCD). Using MIR16 as a normalization control as previously described [42], HCC tumor tissue (375 TCGA datasets) presented significantly lower expression levels of MIR29A than that of normal tissue (51 TCGA datasets) \( (p < 0.01; \text{Figure 1A}) \). In addition, serum MIR29A expression normalized to MIR16 in HCC patients and non-cancer individuals from the Gene Expression Omnibus (GEO) dataset presented a similar trending \( (p < 0.001; \text{Figure 1B}) \). The number (%) of HCC patients presenting a lower value than normal individuals at the cut-off of maximum, mean + 1SD, mean, mean-1SD, and minimum value of normal serum was \( 315/317 (99.4%), 311/317 (98.1%), 229/317 (72.2%), 165/317 (52.1), \) and \( 7/317 (2.2%) \), respectively (Figure 1C). We then asked whether MIR29A gene alteration in HCC plays a factor in its expression change. In this regard, we surveyed the MIR29A data with regard to structural variant, mutation, and copy number alterations (CNA) from TCGA PanCancer Atlas Studies using the cBioPortal web platform, where 10,953 patients/10,967 samples are included as of 26 May 2021. In HCC, MIR29A presented a 1.084% alteration frequency in amplification without the presence of deletion and mutation (Supplementary Figure S1), indicating that copy number alteration, deletion, and mutation scarcely contribute to an expression change of MIR29A. In addition, MIR29A expression between male and female HCC tissue showed no difference (Supplementary Figure S2), suggesting no potential gender bias acting on its expression in HCC tissue. Additionally, we determined the diagnostic value of serum MIR29A using a receiver operating characteristic (ROC) curve and noted that MIR29A presented good diagnostic accuracy for the discrimination of disease, with an area under curve (AUC) of 0.751 (95% CI: 0.711–0.792, \( p < 0.0001 \)) (Figure 1D). Next, UALCAN web server-accessed TCGA datasets revealed that the mRNA of LOX, LOXL2, and VEGFA presented elevated expression levels in HCC tissue as compared to that in normal tissue \( (p < 0.001; \text{Figure 1E–G}) \).

The correlation between the expression of MIR29A, LOX, LOXL2, and VEGFA and corresponding clinical follow-up information was analyzed by Kaplan–Meier curves and the log-rank test. High MIR29A expression was found to be associated with increased overall survival (OS) \( (HR = 0.43; p = 0.0032) \) (Figure 2A), while high expression of LOX (HR = 1.63; \( p = 0.011 \)) (Figure 2B), LOXL2 (HR = 2.06; \( p = 0.016 \)) (Figure 2C), and VEGFA (HR = 1.69; \( p = 0.0057 \)) (Figure 2D) was associated with decreased OS. These results indicate that the downregulated MIR29A and upregulated LOX, LOXL2, and VEGFA predicts poor prognosis, serve as an independent prognostic panel, and may contribute to HCC progression.

2.2. MIR29A Act as A Common Supressor of LOX, LOXL2, and VEGFA

The contrary expression pattern between MIR29A and the aforementioned mRNAs in HCC tissue prompted us to ask whether MIR29A presents a pathway-centric manner on modulating the genes responsible for hypoxic adaptation, matrix remodeling, and angiogenesis. We conducted gene functional enrichment analysis to examine the microRNA-interacting network of LOX, LOXL2, and VEGFA using GSCALite and TargetScan Release 7.2. As shown in Figure 3, MIR29A-3p acts as a central hub in regulating LOX, LOXL2, and VEGFA (Figure 3A,B) via putative binding at the 3’UTR (Figure 3C). We then verified the bioinformatic prediction by an in vitro experimental setting, where overexpression of MIR29A-3p in human HCC cell line HepG2 significantly inhibited the gene and protein expression of LOX (Figure 4A,B), LOXL2 (Figure 4C,D), and VEGFA (Figure 4E,F) (all \( p < 0.05 \)). Additionally, the molecular interaction at posttranscriptional level was corroborated by luciferase reporter assay. As shown in Figure 5A,B, the pMIR-REPORTER™ plasmid comprises a strong protomer CMV to drive the expression of luciferase that is fused with the 3’UTR sequence of LOX or VEGFA (Figure 5A,B). Binding of MIR29A-3p to
wild type 3’UTR leads to reduced luciferase signal, whereas the 3’UTR mutant serves as a negative control. Overexpression of MIR29A-3p suppressed the reported luciferase activity of wild type but not that of mutant, as compared to the negative control (NC)-treated group (all \( p < 0.05 \)) (Figure 5C,D), revealing that the direct binding to LOX 3’UTR and VEGFA 3’UTR accounts for the suppression activity of MIR29A-3p.

Figure 1. Differential expression analysis of MIR29A, LOX, LOXL2, and VEGFA in HCC patients as compared to normal individuals. (A) Heatmap of MIR29A expression level in normal tissue and HCC, wherein 51 and 375 TCGA datasets were respectively accessed in the OncoMir Cancer Database (OMCD). MIR16 expression level served as normalization control. ** \( p < 0.01 \) between normal and HCC group. The raw data of TCGA samples retrieved from OMCD are shown in Supplementary File S1. (B) Serum MIR29A expression level of HCC patient and non-cancer individuals retrieved from the GSE113740 dataset. MIR16 expression level served as the normalization control. *** \( p < 0.001 \) between the non-cancer (Non) and HCC group. (C) The number (%) of HCC patients presenting a lower value than normal individuals at the cut-off of maximum, mean + 1SD, mean, mean-1SD, and minimum value of normal serum. (D) Receiver operating characteristic (ROC) curves for non-cancer and HCC cohorts based on serum MIR29A levels from the GSE113740 dataset. The gene expression level of LOX (E), LOXL2 (F), and VEGFA (G) in HCC and normal tissue retrieved from TCGA datasets. ** \( p < 0.01 \), *** \( p < 0.001 \) between the normal and HCC group. Panel E, F and G were adapted form UALCAN, which is an open assessed web server.

Figure 2. Prognostic value of MIR29A, LOX, LOXL2, and VEGFA in HCC patients. Kaplan–Meier survival analysis representing the probability of the overall survival (OS) in HCC patients based on low vs. high expression of MIR29A (A), LOX (B), LOXL2 (C), and VEGFA (D). HR, hazard ratio.
bioinformatic prediction by an in vitro experimental setting, where overexpression of MIR29A-3p in human HCC cell line HepG2 significantly inhibited the gene and protein expression of LOX (Figure 4A, B), LOXL2 (Figure 4C, D), and VEGFA (Figure 4E, F) (all \( p < 0.05 \)). Additionally, the molecular interaction at posttranscriptional level was corroborated by luciferase reporter assay. As shown in Figure 5A, B, the pMIR-REPORTERTM plasmid comprises a strong protomer CMV to drive the expression of luciferase that is fused with the 3′UTR sequence of LOX or VEGFA (Figure 5A, B). Binding of MIR29A-3p to wild type 3′UTR leads to reduced luciferase signal, whereas the 3′UTR mutant serves as a negative control. Overexpression of MIR29A-3p suppressed the reported luciferase activity of wild type but not that of mutant, as compared to the negative control (NC)-treated group (all \( p < 0.05 \)) (Figure 5C, D), revealing that the direct binding to LOX 3′UTR and VEGFA 3′UTR accounts for the suppression activity of MIR29A-3p.

Figure 3. Bioinformatic identification of MIR29A as a common suppressor for LOX, LOXL2, and VEGFA in HCC. (A) microRNA-interacting network of LOX, LOXL2, and VEGFA in the TCGA cohort of HCC. (B) The enlargement of MIR29A-3p-controlled network, revealing targeted genes LOX, LOXL2, and VEGFA. (C) MIR29A-3p putative binding to the 3′UTR of LOX, LOXL2, and VEGFA were predicted by bioinformatic survey of TargetScan Release 7.2.

2.3. Overexpression of MIR29A Might Induce Apoptosis Signaling and Inhibits Wound Healing Performance and Viability in HCC Cells

We then evaluated the effect of overexpression of MIR29A-3p mimics on the metastatic behaviors of HCC cells. As shown in Figure 6, overexpression of MIR29A-3p mimics induced a significant increase in the markers representing activated apoptosis signaling, including the increased ratio of cleaved/non-cleaved caspase-9 (Figure 6A), cleaved caspase-3 (Figure 6B), and cleaved poly (ADP-ribose) polymerase (PARP) (Figure 6C). Additionally, the wound healing assay showed that overexpression of MIR29A-3p mimics features a suppressive effect on cellular wound healing performance (Figure 6D,E). WST-1 assay revealed an overexpression of MIR29A-3p mimics saps cell viability (Figure 6F). Together, these results indicate that MIR29A acts toward the impeded metastatic behaviors of HCC cells.
**Figure 4.** Overexpression of MIR29A suppresses the gene and protein expression of LOX, LOXL2, and VEGFA. Human HCC HepG2 cells were treated with transfection reagent as a control (Ctrl), miR negative control sequence (NC), or MIR29A-3p mimic (mimic). Then, cell specimens of at least four independent experiments were processed for the detection of gene and protein expression levels of LOX (A, B), LOXL2 (C, D), and VEGFA (E, F) by using qPCR and western blot. 18S in qPCR was used for the normalization gene, while GAPDH in western blot served as the loading control. * p < 0.05, ** p < 0.01, *** p < 0.001 between the indicated groups.

**Figure 5.** MIR29A-3p exerts a suppressive activity by directly targeting the 3′ UTR of LOX and VEGFA. A schematic illustration of the pMIR-REPORTER™ plasmid for the cytomegalovirus (CMV)-driven luciferase reporter assay for MIR29A-3p on LOX (A, C) and VEGFA (B, D). Nucleotides in red denotes mismatched mutation as compared to that of wild type. After transfection of the pMIR-REPORTER™ plasmid, HepG2 cells were treated with transfection reagent transfection reagent as a control (Ctrl), miR negative control sequence (NC), or MIR29A-3p mimic (mimic), followed by the detection of luciferase activity. * p < 0.05, *** p < 0.001 between the indicated groups.
2.3. Overexpression of MIR29A-3p Might Induce Apoptosis Signaling and Inhibits Wound Healing Performance, and Viability. HepG2 cells treated with transfection reagent as a control (Ctrl), MIRs negative sequence (NC), or MIR29A-3p mimic (mimic) for 24 h, followed by further assays. The activity of apoptosis signaling was examined by probing the cleaved (37 and 35 kDa)/non-cleaved (46 kDa) caspase-9 (CASP9) (A), cleaved caspase-3 (CASP3) (B), and cleaved poly (ADP-ribose) polymerase (PARP) (C). GAPDH as loading control. The ratio of cleaved/non-cleaved CASP9, and the GAPDH-normalized cleaved CASP3 and cleaved PARP were analyzed for the densitometric quantification. (D) Representative image at 0 h and 120 h of wound healing assay. (E) Quantification histogram of the changed area percentage (ΔArea%) of the scratched ditch determined by the migrated cells. (F) Cell viability detected by WST-1-based OD450 signal. *p < 0.05, **p < 0.01, ***p < 0.001 between indicated groups.

3. Discussion

In this study, we demonstrated that MIR29A, LOX, LOXL2, and VEGFA represent a panel of differential biomarkers and independent prognostic factors for HCC patients and that MIR29A acts as a common suppressor on these genes to impede the metastatic behaviors of HCC. The proposed model of the clinical value and the mechanism underlying MIR29A-centric pathways is illustrated in Figure 7.

There are a number of studies reporting that low expression of MIR29A represents a biomarker and a predictor for poor outcome in HCC patients [43–46], whereas a few reports showed an opposite expression manner [47,48]. In this study, a decreased expression of MIR29A is noted in HCC tissue as compared to that of normal tissue and serves as an independent factor for poor OS, in support of the aforementioned reports [43–46]. Zhu et al. and Xue et al. reported increased serum MIR29A as a diagnostic factor of HCC [42,49], while our study demonstrated that serum MIR29A expression was in parallel with that of tissue and exhibited a good diagnostic accuracy.

Although MIR29A-activated metastasis-suppression signaling pathways involving carcinogenesis, epigenetics, metabolic adaptation, and immunomodulation in HCC have been noted [39], its role in regulating factors modeling the structure of TME was yet to be clarified. In this regard, our study identified MIR29A as a common suppressor for LOX,
LOXL2, and VEGFA, which notably present a panel of diagnostic and prognostic factors along with MIR29A. As such, this finding provides new insights into clinical decision-making and the development of predictive settings for HCC.

There are increasing reports demonstrating the promising effect of targeting hypoxia-responsive genes, such as LOX, LOXL2, and VEGFA. For instance, a couple of drugs targeting LOX family members are in the early stage of clinical trials [5], including pancreatic and colorectal adenocarcinoma [10,11]. Sorafenib was shown to hit the first breakthrough systemic therapy for treating advanced HCC via disrupting VEGF signaling [50]. Three angiogenesis inhibitor, Trebananib, rebastanib, and MEDI3617, have been evaluated in phase I and II clinical trials [51]. Despite the present lack of HCC trial using approaches targeting the activity of LOX family members, further investigation into broadening the horizons of this issues and the therapeutic strategy widely targeting critical factors are promising. In this study, we demonstrated the biological role of MIR29A in comprehensively inhibiting LOX, LOXL2, and VEGFA and its effect on counteracting metastatic behaviors by inducing apoptosis and repressing cell viability and wound healing performance, indicating the potential of MIR29A as an adjuvant therapy that may further enhance the treatment effectiveness of the targeting therapy for HCC. Nevertheless, further studies mimicking the physiological circumstance such as in vivo evaluation is warranted to clarify the safety and efficacy in a preclinical setting.

In summary, this study provides novel insight into a clinically applicable panel consisting of MIR29, LOX, LOXL2, and VEGFA and demonstrates an anti-HCC effect of MIR29A via comprehensively suppressing the expression of LOX, LOXL2, and VEGFA, paving the way to a prospective theragnostic approach for HCC.

4. Materials and Methods
4.1. Analysis of Gene Differential Expression and Prognostic Significance

The MIR29A expression levels in HCC and normal liver tissue were analyzed using the OncoMiR Cancer Database (OMCD) web server, a repository enabling systemic comparative genome analysis of miR expression sequencing data derived from over 10,000 cancer patients with associated clinical information and organ-specific controls present in The Cancer Genome Atlas (TCGA) database [52]. The raw data of TCGA samples retrieved from OMCD
are shown in Supplementary File 1. Serum MIR29A expression levels in HCC and non-cancer cohorts were analyzed using National Center for Biotechnology Information Gene Expression Omnibus (GEO) database (available online: http://www.ncbi.nlm.nih.gov/geo (accessed on 25 April 2021)) [53], GSE113740. The comparison of the gene expression level in HCC and normal tissue was undertaken in UALCAN web server [54], which facilitates access to publicly available cancer OMICS data, such as TCGA and Clinical Proteomic Tumor Analysis Consortium (CPTAC). MIR16 served as normalization control as previously described [42].

Kaplan–Meier analysis, which was used to determine the prognostic value of biomarkers, was conducted in the Kaplan-Meier plotter web server (available online: https://kmplot.com/analysis/ (accessed on 25 April 2021)), which includes data sources from GEO, European Genome-phenome Archive (EGA), and TCGA to enable the assessment of the effect of 54 k genes, including mRNA, miR, and protein on survival in 21 cancer types [55]. The prognostic value of miR and mRNA was evaluated by using the panel miR-power for liver cancer [56] and RNA-seq for liver cancer [57] of the KM plotter, respectively.

4.2. Bioinformatic Analysis of MIR29A-mRNA Interaction

The microRNA interacting network of LOX, LOXL2, and VEGFA2 was retrieved from GSCALite, which is a gene set cancer analysis platform that integrates cancer genomic data from the TCGA [58]. Prediction of MIR29A-5p/-3p interaction was conducted using the TargetScan release 7.2 database (available online: http://www.targetscan.org/vert_72/ (accessed on 25 April 2021)) [59].

4.3. Cell Culture and Transfection

Human HCC cell line HepG2 were purchased from American Type Tissue Collection (ATCC) and cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS; 10437-028, Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin/streptomycin (15240-062, Thermo Fisher Scientific). The oligonucleotides of the MIR29A mimics and their corresponding MIR negative control were purchased from GE Healthcare Dharmacon (C-300504-07-0050 and CN-001000-01-50, respectively). The transfection of MIR29A mimics and the negative control was carried out with Lipofectamine™ RNAiMAX Transfection Reagent (13778-150, Invitrogen, Carlsbad, CA, USA). Cells were collected 24 h after transfection for further experiments.

4.4. Luciferase Reporter Assay

To investigate the molecular basis of MIR29A-3p acting on LOX and VEGFA, HepG2 cells were respectively transfected with pMIR-LOX-3′UTR and pMIR-VEGFA-3′UTR followed by transfection of reagent only, MIR negative sequence, or MIR29A-3p mimic. Cells transfected with pMIR-LOX-3′UTR mutant and pMIR-VEGFA-3′UTR mutant served as the negative control. Specifically, the sequence of wild type 3′UTR or mutated 3′UTR were cloned into the multiple cloning site after the CMV-driven luciferase (Figure 3B) of the pMIR-REPORTER™ plasmid (AM5795, Thermo Fisher Scientific, Rockford, IL, USA). Then, HepG2 cells were seeded at 1.8 × 10⁵ cells in a 100 mm dish for 18 h. Next, 6 µg reporter plasmids were transfected into a 100 mm dish cultivating HepG2 cells in the presence of Turbofect transfection reagent (R0531, Thermo Fisher Scientific, Rockford, IL, USA) for 20 h. HepG2 were subsequently trypsinized and seeded at 9 × 10⁵ cells in a 60 mm dish with fresh growth medium. Furthermore, 25 nM MIR29A-3p mimic (C-300504-07-0050, GE Healthcare Dharmacon, IN, USA), MIR negative control (CN-001000-01-50, GE Healthcare Dharmacon), or no-sequence control (Ctrl) were transfected into cells in the presence of RNAiMAX transfection reagent (#13778-150, Invitrogen, Carlsbad, CA, USA) for 24 h. Finally, cells were lysed for the detection of luciferase signal with Neolite Reporter Gene Assay System (PerkinElmer, Waltham, MA, USA).
4.5. Quantitative Real-Time PCR (qPCR)

Total RNA of the cells was extracted by using TRIzol® reagent (15596026, Invitrogen, Carlsbad, CA, USA) and then underwent reverse transcription to yield cDNA with an oligodeoxynucleotide primer (oligo dT15)-based method according to the manufacturer’s protocol (M1701, Promega, Madison, WI, USA). The qPCR reaction was undertaken using 2 × SYBR Green PCR Master Mix (04887352001, Roche Molecular Systems, Inc., Pleasanton, CA, USA) on LightCycler480® (Roche). Each PCR reaction included 0.5 µM forward and reverse primers, 30 ng of cDNA, and 1 × SYBR Green PCR Master Mix in a total reaction volume of 10 µL. For qPCR program, an initial amplification was done with a denaturation step at 95 °C for 10 min, followed by 45 cycles of denaturation at 95 °C for 30 s, primer annealing at 62 °C for 15 s, and primer extension at 72 °C for 25 s, followed by melting curve analysis. The primer sequences for human genes were shown in Table 1.

| Table 1. Sequence of primers pairs. |
|-------------------------------------|
| Forward Primer | Reverse Primer |
|----------------|----------------|
| LOX 5’-CAGCATCAATGGGAGAAGC-3’ | 5’-GCTGAGGCTGTAAGATGG-3’ |
| LOXL2 5’-CTGCACGATCGACATCC-3’ | 5’-TAGCGGCTCCTGAGATTT-3’ |
| VEGFA 5’-AAAGGCGAAAACGAGAAGA-3’ | 5’-GCTCAGGGCATGACGCAG-3’ |
| 18S 5’-GTAACCGGTAGACATCCT-3’ | 5’-CCATCCAGCAATGATCCAGG-3’ |

4.6. Western Blotting

The western blotting procedure was compatible with a quantitative approach, as described previously [60]. Briefly, approximately 1 × 10^6 cells were lysed in protein lysis buffer (17081, iNtRON Biotechnology, Seongnam, Korea), homogenized, and then centrifuged. The resulting supernatant lysates underwent protein quantitation measurement using Bio-RAD protein assay, in accordance with the manufacturer’s protocol (LIT33, Bio-RAD, Hercules, CA, USA). The bovine serum albumin (BSA) was used as a standard to construct a standard curve for the relative quantitation of the proteins in the samples. Next, 40 µg of protein was separated in 8–15%SDS-PAGE, which was then transferred onto PVDF membrane and incubated with primary antibodies at 4 °C overnight. The primary antibodies included LOX (1:1000; NB100-2527, Novus, CO, USA), LOXL2 (1:1000; GTX105085, GeneTex, Irvine, USA), VEGFA (1:1000; ab46154, Abcam, Cambridge, UK), caspase 9 (1:1000; 10380-1-AP, Proteintech, Rosemont, IL, USA), cleaved caspase-3 (1:1000; #9661, Cell Signaling Technology, MA, USA), cleavedPARP (1:1000; #9541, Cell Signaling Technology, MA, USA), and GAPDH (1:100,000; 60004-1-lg, Proteintech). After washing twice with TBST solution, PVDF membrane was incubated with secondary antibodies, such as horseradish peroxidase-coupled anti-rabbit immunoglobulin-G antibodies (1:5000; NEF812001EA, PerkinElmer, Waltham, MA, USA) or HRP anti-mouse immunoglobulin-G antibodies (1:10,000; NEF822001, PerkinElmer) at room temperature for 1 h. The blots were developed with an ECL Western blotting system and exposed them to film (GE28-9068-37, GE Healthcare, Chicago, IL, USA). The signals were quantified by using Quantity One® 1-D analysis software (Bio-Rad Laboratories, Hercules, CA, USA). The accurate quantitative value of the target protein was normalized by its corresponding GAPDH.

4.7. Wound Healing Assay

Wound healing assay was employed to detect the wound healing performance of the cells. In each culture-insert, 5 × 10^5 HepG2 cells were seeded (ibidi culture-insert 2 well, ibidi GmbH, Martinsried, Germany) overnight to allow attachment. Then, the culture-insert was removed, thereby creating a bar of wound. Furthermore, PBS was used to wash out the unattached cells. After the transfection of 25 nM MIR29A mimics and their corresponding MIR negative control, the culture plate was photographed to document the width of the wound under a light microscope (50× magnification) at 0 and 120 h. The area of the wound was quantified using imageJ Version 1.53i.
4.8. Cell Viability Assay

WST-1 assay was used to determine the cell viability. In each 96-well, $5 \times 10^5$ HepG2 cells were seeded at a volume of 100 $\mu$L. After attachment, cells were transfected with 25 nM MIR29A mimics and their corresponding MIR negative control for 24 h, followed by the addition of 10 $\mu$L WST-1 reagent (Roche Diagnostics, Laval, QC, Canada) for another 1 h at 37 °C. The absorbance signal was measured using a microplate reader (Hidex Sense microplate reader, Turku, Finland) at a test wavelength of 450 nm and reference wavelength of 630 nm.

4.9. Statistical Analysis

All values are expressed as mean ± standard error (SE). Quantitative data were analyzed using unpaired t-test for two-group comparison or one-way analysis of variance for three-or-more-group comparison when appropriate. Least significant difference (LSD) test was used for post-hoc analysis. Two-sided $p$-values less than 0.05 were considered to be statistically significant.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ijms22116001/s1.

Author Contributions: Conceptualization, Y.-L.Y., H.-Y.L. and Y.-H.H.; methodology, H.-Y.L. and M.-C.T.; software, H.-Y.L. and Y.-H.C.; validation, C.-C.W., and P.-Y.C.; formal analysis, P.-Y.C.; investigation, P.-Y.C.; resources, Y.-H.H.; data curation, H.-Y.L., M.-C.T. and Y.-H.C.; writing—original draft preparation, Y.-L.Y., H.-Y.L. and P.-Y.C.; writing—review and editing, H.-Y.L. and Y.-H.H.; visualization, H.-Y.L.; supervision, P.-Y.C.; project administration, Y.-L.Y. and Y.-H.H.; funding acquisition, Y.-L.Y. and Y.-H.H. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by grants from the Ministry of Science and Technology, Taiwan (106-2314-B-182A-141-MY3, 108-2314-B-182A-066-, 108-2811-B-182A-509, 106-2314-B-442-001-MY3, 109-2314-B-442-001, and 109-2314-B-075B-002), National Health Research Institutes (NHRI-109BCCO-MF20215-01), Chang Gung Memorial Hospital, Taiwan (CMRPG8K1071 and CMRPG8K0981), and Show Chwan Memorial Hospital, Taiwan (SRD-109023, SRD-109024, SRD-109025, RD107063, and SRD-110008). However, these organizations had no part in the study design, data collection and analysis, publication decisions, or preparation of the manuscript.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article or Supplementary Material.

Acknowledgments: The authors would like to thank Yuan-Ting Chuang and Chia-Ling Wu for assisting with this article.

Conflicts of Interest: The authors hereby declare no conflicts of interest with regard to this article.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249.
2. Aly, A.; Ronnebaum, S.; Patel, D.; Doleh, Y.; Benavente, F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: A systematic literature review. Hepat. Oncol. 2020, 7, HEP27.
3. Llovet, J.M.; Zucman-Rossi, J.; Pikarsky, E.; Sangro, B.; Schwartz, M.; Sherman, M.; Gores, G. Hepatocellular carcinoma. Nat. Rev. Dis. Printers 2016, 2, 16018. [CrossRef]
4. Ye, M.; Song, Y.; Pan, S.; Chu, M.; Wang, Z.W.; Zhu, X. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy. Pharmacol. Ther. 2020, 215, 107633. [CrossRef] [PubMed]
5. Lin, H.Y.; Li, C.J.; Yang, Y.L.; Huang, Y.H.; Hsiau, Y.T.; Chu, P.Y. Roles of lysyl oxidase family members in the tumor microenvironment and progression of liver cancer. Int. J. Mol. Sci. 2020, 21, 9751. [CrossRef] [PubMed]
6. Yang, M.; Liu, J.; Wang, F.; Tian, Z.; Ma, B.; Li, Z.; Wang, B.; Zhao, W. Lysyl oxidase assists tumorinitiating cells to enhance angiogenesis in hepatocellular carcinoma. Int. J. Oncol. 2019, 54, 1398–1408. [PubMed]
7. Umezaki, N.; Nakagawa, S.; Yamashita, Y.I.; Kitano, Y.; Arima, K.; Miyata, T.; Hiyoshi, Y.; Okabe, H.; Nitta, H.; Hayashi, H.; et al. Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma. *Cancer Sci.* 2019, 110, 2033–2043. [CrossRef] [PubMed]

8. Fan, Z.; Zheng, W.; Li, H.; Wu, W.; Liu, X.; Sun, Z.; Hu, H.; Du, L.; Jia, Q.; Liu, Q. LOXL2 upregulates hypoxia-inducible factor1alpha signaling through SnaflPBP1 in hepatic carcinoma cells. *Onco. Rep.* 2020, 43, 1641–1649.

9. Wu, S.; Zhang, X.; Xing, D.; Dong, Y.; Wang, Y.; You, Y.; Chen, R.; Hu, C.; Chen, J.; Gao, D.; et al. Matrix stiffness-upregulated LOXL2 promotes fibroblast production, MMP9 and CXCL12 expression and BMDC recruitment to aid pre-metastatic niche formation. *J. Exp. Clin. Cancer Res.* 2018, 37, 99. [CrossRef] [PubMed]

10. Hecht, J.R.; Benson, A.B.; 3rd; Vyushkov, D.; Yang, Y.; Bellendi, J.; Verma, U. A Phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the second-line treatment of metastatic KRAS mutant colorectal adenocarcinoma. *Oncologist* 2017, 22, 243-e23. [CrossRef]

11. Benson, A.B., 3rd; Wainberg, Z.A.; Hecht, J.R.; Vyushkov, D.; Dong, H.; Bellendi, J.; Kudrik, F. A Phase II Randomized, Double-Blind, Placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma. *Oncologist* 2017, 22, 241-e15. [CrossRef] [PubMed]

12. Finn, R.S.; Zhu, A.X. Targeting angiogenesis in hepatocellular carcinoma: Focus on VEGF and bevacizumab. *Expert Rev. Anticancer Ther.* 2009, 9, 503–509. [CrossRef]

13. Wang, X.; He, Y.; Mackowiak, B.; Gao, B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. *Gut* 2021, 70, 784–795. [CrossRef]

14. Zhang, Z.; Zou, J.; Wang, G.K.; Zhang, J.T.; Huang, S.; Qin, Y.W.; Jing, Q. Uracils at nucleotide position 9-11 are required for the rapid turnover of miR-29 family. *Nucleic Acids Res.* 2011, 39, 4387–4395. [CrossRef] [PubMed]

15. Muller, M.; Jakel, L.; Bruinsma, I.B.; Claassen, J.A.; Kuiperij, H.B.; Verbeek, M.M. MicroRNA-29a Is a candidate biomarker for Alzheimer’s Disease in cell-free cerebrospinal fluid. *Mol. Neurobiol.* 2016, 53, 2894–2899. [CrossRef]

16. Goh, S.Y.; Chao, Y.X.; Dheen, S.T.; Tan, E.K.; Solladay, S.; Lee, Y.K. Role of MicroRNAs in Parkinson’s Disease. *Int. J. Mol. Sci.* 2019, 20, 5649. [CrossRef] [PubMed]

17. Huang, J.; Song, G.; Yin, Z.; Fu, Z.; Ye, Z. MiR-29a and Messenger RNA expression of bone turnover markers in canonical wnt pathway in patients with ankylosing spondylitis. *Clin. Lab.* 2017, 63, 955–960. [CrossRef]

18. Huang, Q.; Cai, A.P.; Chen, J.Y.; Huang, C.; Li, J.; Feng, Y.Q. The Relationship of Plasma miR-29a and oxidized low density lipoprotein with atherosclerosis. *Cell Physiol. Biochem.* 2016, 40, 1521–1528. [CrossRef]

19. Zhao, Y.; Yuan, Y.; Qiu, C. Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. *Med. Sci. Monit.* 2016, 22, 2175–2181. [CrossRef]

20. Afum-Adjei Awuah, A.; Ueberberg, B.; Owusu-Dabo, E.; Frempong, M.; Jacobsen, M. Dynamics of T-cell IFN-gamma and miR-29a pathway in patients with ankylosing spondylitis. *Circ. Cardiovasc. Genet.* 2011, 4, 600–606. [CrossRef] [PubMed]

21. Jones, J.A.; Stroud, R.E.; O’Quinn, E.C.; Black, L.E.; Barth, J.L.; Elefteriades, J.A.; Bavaria, J.E.; Gorman, J.H., 3rd; Gorman, R.C.; Spinale, F.G.; et al. Selective microRNA suppression in human thoracic aneurysms: Relationship of miR-29a to aortic size and proteolytic induction. *Circ. Cardiovasc. Genet.* 2011, 4, 605–613. [CrossRef]

22. Miller, N.L.; Gilchrist, D.S.; Akbar, M.; Reilly, J.H.; Kerr, S.C.; Campbell, A.L.; Murrell, G.A.C.; Liew, F.Y.; Kurosawa-Stolarska, M.; McInnes, I.B. MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. *Nat. Commun.* 2015, 6, 6774. [CrossRef] [PubMed]

23. Hu, Y.C.; Chang, P.J.; Ho, C.; Huang, Y.T.; Shih, Y.H.; Wang, C.J.; Lin, C.L. Protective effects of miR-29a on diabetic glomerular dysfunction by modulation of DKK1/Wnt/beta-catenin signaling. *Sci. Rep.* 2016, 6, 30575. [CrossRef] [PubMed]

24. Kawashita, Y.; Jininn, M.; Makino, T.; Kajihara, I.; Makino, K.; Honda, N.; Masuguchi, S.; Fukushima, S.; Inoue, Y.; Ihn, H. Circulating miR-29a levels in patients with scleroderma spectrum disorder. *J. Dermatol. Sci.* 2011, 61, 67–69. [CrossRef] [PubMed]

25. Goldschmidt, I.; Thum, T.; Baumann, U. Circulating miR-21 and miR-29a as Markers of disease severity and etiology in cholestatic pediatric liver disease. *J. Clin. Med.* 2016, 5, 28. [CrossRef] [PubMed]

26. Lin, H.Y.; Yang, Y.L.; Wang, P.W.; Wang, F.S.; Huang, Y.H. The emerging role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in modulating oxidative stress, inflammation, and beyond. *Cells* 2020, 9, 1041. [CrossRef] [PubMed]

27. Huang, Y.H.; Kuo, H.C.; Yang, Y.L.; Wang, F.S. MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation. *Int. J. Med. Sci.* 2019, 16, 212–220. [CrossRef]

28. Huang, Y.H.; Tao, M.M.; Huang, L.T.; Chuan, J.H.; Kuo, K.C.; Yang, Y.L.; Wang, F.S. Activation of Mir-29a in activated hepatic stellate cells modulates its profibrogenic phenotype through inhibition of histone deacetylases 4. *PLoS ONE* 2015, 10, e0136453. [CrossRef] [PubMed]

29. Huang, Y.H.; Yang, Y.L.; Huang, F.C.; Tao, M.M.; Lin, Y.C.; Tsai, M.H.; Wang, F.S. MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice. *Exp. Biol. Med.* 2018, 243, 13–21. [CrossRef] [PubMed]

30. Huang, Y.H.; Yang, Y.L.; Wang, F.S. The Role of miR-29a in the regulation, function, and signaling of liver fibrosis. *Int. J. Mol. Sci.* 2018, 19, 1889. [CrossRef]

31. Li, S.C.; Wang, F.S.; Yang, Y.L.; Tao, M.M.; Chuan, J.H.; Huang, Y.H. Microarray study of pathway analysis expression profile associated with MicroRNA-29a with regard to murine cholestatic liver injuries. *Int. J. Mol. Sci.* 2016, 17, 324. [CrossRef]
32. Lin, H.Y.; Wang, F.S.; Yang, Y.L.; Huang, Y.H. MicroRNA-29a Suppresses CD36 to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice. *Cells* 2019, 8, 1298. [CrossRef]

33. Lin, Y.C.; Wang, F.S.; Yang, Y.L.; Huang, Y.H. MicroRNA-29a Disrupts DNMT3b to Ameliorate the Role of miR-29a in Hepatocellular Carcinoma. *Int. J. Mol. Sci.* 2021, 22, 3036. [CrossRef]

34. Mahati, S.; Xiao, L.; Yang, Y.; Mao, R.; Bao, Y. miR-29a suppresses growth and migration of hepatocellular carcinoma via Regulating the microRNA-29a/Signal transducer and activator of transcription 3 Axis. *Oncol. Targets Ther.* 2017, 11, e72359. [CrossRef]

35. Shi, Y.; Kong, W.; Lu, Y.; Zheng, Y. Traditional Chinese Medicine Xiaoai Jiedu recipe suppresses the development of hepatocellular carcinoma. *Apoptosis* 2017, 22, 1223. [CrossRef]

36. Zhang, Y.; Yang, L.; Wang, S.; Liu, Z.; Xiu, M. MiR-29a suppresses cell proliferation by targeting SIRT1 in hepatocellular carcinoma. *PLoS ONE* 2013, 8, e2906. [CrossRef] [PubMed]

37. Zhu, H.T.; Dong, Q.Z.; Sheng, Y.Y.; Wei, J.W.; Wang, G.; Zhou, H.J.; Ren, N.; Jia, H.L.; Ye, Q.H.; Qin, L.X. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. *PLoS ONE* 2012, 7, e52393. [CrossRef] [PubMed]

38. Zhu, H.T.; Hasan, A.M.; Liu, R.B.; Zhang, Z.C.; Zhang, X.; Wang, J.; Wang, H.Y.; Wang, F.; Shao, J.Y. Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma. *Oncotarget* 2016, 7, 45637–45648. [CrossRef] [PubMed]

39. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol.* 2021, 69, 82–236. [CrossRef] [PubMed]

40. Yang, L.; Engeland, C.G.; Cheng, B. Social isolation impairs oral palatal wound healing in Sprague-Dawley rats: A role for miR-29. *BMC Biophys.* 2018, 968–886. [CrossRef] [PubMed]

41. Dey, S.; Kwon, J.J.; Liu, S.; Hodge, G.A.; Taleb, S.; Zimmers, T.A.; Wan, J.; Kota, J. miR-29a Is Repressed by MYC in Pancreatic Carcinoma via Regulation of Phosphoinositide 3-Kinase p85 Alpha. *Int. J. Mol. Sci.* 2021, 20, 311–323. [CrossRef]

42. Xue, X.; Zhao, Y.; Wang, X.; Qin, L.; Hu, R. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. *J. Cell Biochem.* 2019, 2021, 135–142. [CrossRef] [PubMed]

43. Shi, Y.; Kong, W.; Lu, Y.; Zheng, Y. Traditional Chinese Medicine Xiaoai Jiedu recipe suppresses the development of hepatocellular carcinoma via Regulating the microRNA-29a/Signal transducer and activator of transcription 3 Axis. *Oncol. Targets Ther.* 2020, 13, 7329–7342. [CrossRef] [PubMed]

44. Zhang, Y.; Yang, L.; Wang, S.; Liu, Z.; Xiu, M. MiR-29a suppresses cell proliferation by targeting SIRT1 in hepatocellular carcinoma. *Cancer Biomark.* 2018, 22, 151–159. [CrossRef] [PubMed]

45. Parpart, S.; Roessler, S.; Dong, F.; Rao, V.; Takai, A.; Ji, J.; Qin, Y.X.; Ye, Q.H.; Jia, H.L.; Tang, Z.Y.; et al. Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. *Hepatology* 2014, 60, 872–883. [CrossRef] [PubMed]

46. Chen, Q.; Yin, D.; Zhang, Y.; Yu, L.; Li, X.D.; Zhou, S.L.; Gao, D.M.; Hu, J.; Jin, C.; et al. MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis. *Cell Death Dis.* 2017, 8, e2906. [CrossRef] [PubMed]

47. Zhao, J.; Pan, B.; Chen, Y.; Yang, L.; Zhu, J.; Wei, J.; Liu, S.; Kang, J.; Wang, G.; et al. MicroRNA-29a regulates expression of alpha-fetoprotein to inhibit the growth of hepatoma cells. *Apoptosis* 2014, 19, 30–41. [CrossRef] [PubMed]

48. Mahati, S.; Xiao, L.; Yang, Y.; Mao, R.; Bao, Y. miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1. *Biochem. Biophys. Res. Commun.* 2017, 486, 732–737. [CrossRef] [PubMed]

49. Parpart, S.; Roessler, S.; Dong, F.; Rao, V.; Takai, A.; Ji, J.; Qin, L.X.; Ye, Q.H.; Jia, H.L.; Tang, Z.Y.; et al. Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. *Hepatology* 2014, 60, 872–883. [CrossRef] [PubMed]

50. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol.* 2020, 72, 192. [CrossRef] [PubMed]

51. Gillen, J.; Richardson, D.; Moore, K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. *Curr. Oncol. Rep.* 2019, 21, 22. [CrossRef]

52. Sarver, A.L.; Sarver, A.E.; Yuan, C.; Subramanian, S. OMCD: OncomiR Cancer Database. *BMC Cancer* 2018, 18, 1223. [CrossRef]

53. Edgar, R.; Domrachev, M.; Lash, A.E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 2002, 30, 207–210. [CrossRef] [PubMed]

54. Chandrashekar, D.S.; Bashel, B.; Balasubramanya, S.A.H.; Creighton, C.J.; Ponce-Rodriguez, I.; Chakravarthi, B.; Varambally, S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival Analyses. *Neoplasia* 2017, 19, 649–658. [CrossRef] [PubMed]

55. Nagy, A.; Munkacsy, G.; Gyoryffy, B. Pancancer survival analysis of cancer hallmark genes. *Sci. Rep.* 2021, 11, 6047. [CrossRef] [PubMed]

56. Nagy, A.; Lanzky, A.; Menyharty, O.; Gyoryffy, B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Sci. Rep.* 2018, 8, 9227. [CrossRef]

57. Menyharty, O.; Nagy, A.; Gyoryffy, B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. *R. Soc. Open Sci.* 2018, 5, 181006. [CrossRef]
58. Liu, C.J.; Hu, F.F.; Xia, M.X.; Han, L.; Zhang, Q.; Guo, A.Y. GSCALite: A web server for gene set cancer analysis. *Bioinformatics* 2018, 34, 3771–3772. [CrossRef]
59. Agarwal, V.; Bell, G.W.; Nam, J.W.; Bartel, D.P. Predicting effective microRNA target sites in mammalian mRNAs. *eLife* 2015, 4, e05005. [CrossRef]
60. Pillai-Kastoori, L.; Schutz-Geschwender, A.R.; Harford, J.A. A systematic approach to quantitative Western blot analysis. *Anal. Biochem.* 2020, 593, 113608. [CrossRef] [PubMed]